FLT3 and acute myeloid leukemia: For the R/R AML cohort, compared with the FLT3wt group, both FLT3mut and FLT3‐ITD groups had lower CR/CRi rates (31.6% vs. 49.5%, p = 0.048; 27.3% vs. 49.5%, p = 0.026, respectively), and similar rates were observed for MRD‐negative cases (50.0% vs. 40.6%, p = 0.325; 44.4% vs. 40.6%, p = 0.654, respectively).